Slide 1: Year End and 4Q 2024 Results Conference Call and Webcast
Year End and 4Q 2024 Results Conference Call and Webcast March 5, 2025 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Year End and 4Q 2024 Earnings Results Call Agenda
Year End and 4Q 2024 Earnings Results Call Agenda Leone Patterson, MBA, CPA Paul Moore, Ph.D. Ken Galbraith EVP, CBO and CFO CSO Chair and CEO • Business Update • R&D Update • Q&A • Financial Update • Q&A • Q&A Making a Meaningful Difference 3
Slide 4: Leone Patterson, MBA, CPA
Leone Patterson, MBA, CPA EVP, CBO and CFO Making a Meaningful Difference 4
Slide 5: 10+ Years of Innovative Multifunctional Antibody Development
10+ Years of Innovative Multifunctional Antibody Development $45M+ milestone payments achieved in relation to partnerships over the past 12 months* Leading the development of next generation antibody-drug conjugates ZW220 & ZW251 Novel Payload Zymelink PreCysion nominations Mechanisms & Hemiasterlin
Slide 6: Full Year 2024 Financial Results
Full Year 2024 Financial Results • Revenue increased in 2024 slightly primarily due to achievement of milestone revenue with Jazz, BeiGene and GSK offset by a decrease in revenue from Jazz for development support and drug In millions USD Full Year 2024 Full Year 2023 supply regarding zanidatamab. •
Slide 7: Projected Cash Runway Supports R&D Priorities into 2H 2027
Projected Cash Runway Supports R&D Priorities into 2H 2027 Current Financial Status: Potential sources to extend cash runway beyond 2H 2027: • Cash resources1 of approx. $324.2M (as of December 31, 2024) • Additional regulatory approval and commercial milestones for zanidatamab from Jazz and • Antic
Slide 8: Paul Moore, Ph.D.
Paul Moore, Ph.D. Chief Scientific Officer Making a Meaningful Difference 8
Slide 9: Maintain Focus on Cancers with Highest Unmet Medical Need
Maintain Focus on Cancers with Highest Unmet Medical Need: Increase GI Tract and Thoracic Cancer Coverage and Expand to Heme-Onc Cancers Therapeutic focus areas | ZYME Development Programs 100 Testis Thyroid Melanoma Prostate HR+ HER2+ BC HR+ HER2- BC HL CLL Endometrial (ZW91, ZW171, ZW220) 80 HR- H
Slide 10: Nominated Clinical Pipeline Programs Target Select Tumor Types
Nominated Clinical Pipeline Programs Target Select Tumor Types Thoracic Gynecological Digestive Tract NSCLC SCLC Ovarian Endometrial Pancreatic HCC ZW171 MSLN x CD3 TCE ZW209 DLL3xCD3xCD28 TCE * ZW191 FRα TOPO1i ADC ZW251 GPC3 TOPO1i ADC ZW220 NaPi2b TOPI1i ADC *Image for Illustrative purposes only
Slide 11: Cancer Immunity and Autoimmunity are Two Sides of the Same Coin
Cancer Immunity and Autoimmunity are Two Sides of the Same Coin • The resounding recent success of cancer immunotherapy has spurred rapid development in precision medicine • Many cancer immunotherapy drugs aim to unleash endogenous cancer responses • The regulatory mechanisms that hold back cancer i
Slide 12: Harnessing Zymeworks' Strengths to Address Autoimmune and Inflammatory Disease
Harnessing Zymeworks' Strengths to Address Autoimmune and Inflammatory Disease Inflammatory Disease: Autoimmune Disease: • Chronic dysregulation of inflammation • Chronic immune responses • Innate immune cells • Lymphocytes • Environmental factors • Self antigens • Amenable to cytokine blockade • Am
Slide 13: ZW171 Clinical Development Progress
ZW171 Clinical Development Progress United Kingdom USA USA UK United Kingdom UK USA SK DEU Germany DEU United States of America South Germany Korea South Korea SK US FDA:U.S. Food and Drug Administration; MFDS: Ministry of Food and Drug Safety. Making a Meaningful Difference 13
Slide 14: ZW191 Clinical Development Progress
ZW191 Clinical Development Progress USA USA Japan JPN USA Australia AU SK JP United States of America South Korea Japan South Korea SK SGP Singapore Singapore SGP AU Australia US FDA: U.S. Food and Drug Administration; PDMA: Prescription Drug Marketing Act; TGA: Therapeutic Goods Administration; MFD
Slide 15: Meaningful Catalyst Events Anticipated Throughout 2025 & 2026
Meaningful Catalyst Events Anticipated Throughout 2025 & 2026 1H 2025 2H 2025 2026 Potential regulatory decisions in Pivotal Phase 3 top-line PFS data Expected IND submission for EU and China expected for readout in 1L GEA for zanidatamab ZW209 (DLL3) in 1H 2026 zanidatamab in 2L BTC with potential
Slide 16: Q&A
Q&A Ken Galbraith Chair & CEO Paul Moore, Ph.D. CSO Leone Patterson, MBA, CPA EVP, CBO and CFO Making a Meaningful Difference 16